WGS to confirm the absence of mutations induced by cell lines treatments with a DNA binding small molecule, able to induce trinucleotide repeat contractions in Huntington's disease cell lines and in v

NIAID Data Ecosystem50

Structure-based exploration of selectivity for ATM inhibitors in Huntingtons disease

药物选择性优化

亨廷顿病治疗

Structure-based exploration of selectivity for ATM inhibitors in Huntingtons disease Descriptor: 4-morpholin-4-yl-6-[(2~{R})-2-(phenylmethyl)pyrrolidin-1-yl]-1~{H}-pyridin-2-one, Phosphatidylinositol

Protein Data Bank Japan2024-01-24 更新40

North America Huntingtons Disease Therapeutics Market

亨廷顿病治疗

区域市场分析

The North America Huntingtons Disease Therapeutics report features an extensive regional analysis, identifying market penetration levels across major geographic areas. It highlights regional growth tr

IMR REPORTS50

Data_Sheet_1_Stimulation of Sphingosine Kinase 1 (SPHK1) Is Beneficial in a Huntington’s Disease Pre-clinical Model.PDF

亨廷顿病治疗

神经保护机制

Although several agents have been identified to provide therapeutic benefits in Huntington disease (HD), the number of conventionally used treatments remains limited and only symptomatic. Thus, it is

NIAID Data Ecosystem40

The use of artificial miRNAs in the therapy of Huntington's Disease

资源简介：

相关数据集